Genetics and epigenetics of NAFLD and NASH: Clinical impact

Journal of Hepatology

Volumn 68, Issue 2, 2018, Pages 268-279

  Eslam, Mohammed ^a   Valenti, Luca ^b   Romeo, Stefano ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Epigenetics; Genetic variation; Non alcoholic fatty liver disease; PNPLA3; Steatohepatitis

Indexed keywords

DNA; FATTY ACID; UNTRANSLATED RNA;

CELL AGING; CHROMATIN; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; FIBROGENESIS; GENE LOCUS; GENETIC BACKGROUND; GENETIC SUSCEPTIBILITY; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HERITABILITY; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; DISEASE EXACERBATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 85033218466     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.09.003     Document Type: Review

References (137)

1. Rinella, M., Charlton, M., The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology 64 (2016), 19–22.
2. Serfaty, L., Lemoine, M., Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 34 (2008), 634–637.
3. Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs. nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654.
4. Eslam, M., George, J., Genetic and epigenetic mechanisms of NASH. Hepatol Int 10 (2016), 394–406.
5. Dongiovanni, P., Anstee, Q.M., Valenti, L., Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 19 (2013), 5219–5238.
6. Schwimmer, J.B., Celedon, M.A., Lavine, J.E., Salem, R., Campbell, N., Schork, N.J., et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 136 (2009), 1585–1592.
7. Willner, I.R., Waters, B., Patil, S.R., Reuben, A., Morelli, J., Riely, C.A., Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 96 (2001), 2957–2961.
8. Makkonen, J., Pietilainen, K.H., Rissanen, A., Kaprio, J., Yki-Jarvinen, H., Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol 50 (2009), 1035–1042.
9. Loomba, R., Rao, F., Zhang, L., Khandrika, S., Ziegler, M.G., Brenner, D.A., et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology 139 (2010), 836–845 e831.
10. Loomba, R., Schork, N., Chen, C.H., Bettencourt, R., Bhatt, A., Ang, B., et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 149 (2015), 1784–1793.
11. Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
12. Guerrero, R., Vega, G.L., Grundy, S.M., Browning, J.D., Ethnic differences in hepatic steatosis: an insulin resistance paradox?. Hepatology 49 (2009), 791–801.
13. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
14. Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008), 1461–1465.
15. Dongiovanni, P., Romeo, S., Valenti, L., Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int, 2015, 2015, 460190.
16. Dongiovanni, P., Donati, B., Fares, R., Lombardi, R., Mancina, R.M., Romeo, S., et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 19 (2013), 6969–6978.
17. Singal, A.G., Manjunath, H., Yopp, A.C., Beg, M.S., Marrero, J.A., Gopal, P., et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol 109 (2014), 325–334.
18. Liu, Y.L., Patman, G.L., Leathart, J.B., Piguet, A.C., Burt, A.D., Dufour, J.F., et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 61 (2013), 75–81.
19. Huang, Y., Cohen, J.C., Hobbs, H.H., Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 286 (2011), 37085–37093.
20. Pingitore, P., Pirazzi, C., Mancina, R.M., Motta, B.M., Indiveri, C., Pujia, A., et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta 1841 (2014), 574–580.
21. Pirazzi, C., Valenti, L., Motta, B.M., Pingitore, P., Hedfalk, K., Mancina, R.M., et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet 23 (2014), 4077–4085.
22. Pingitore, P., Dongiovanni, P., Motta, B.M., Meroni, M., Lepore, S.M., Mancina, R.M., et al. PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis. Hum Mol Genet 25 (2016), 5212–5222.
23. BasuRay, S., Smagris, E., Cohen, J., Hobbs, H.H., The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology 66 (2017), 1111–1124.
24. Donati, B., Motta, B.M., Pingitore, P., Meroni, M., Pietrelli, A., Alisi, A., et al. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. Hepatology 63 (2016), 787–798.
25. Valenti, L., Dongiovanni, P., Mutant PNPLA3 I148M protein as pharmacological target for liver disease. Hepatology 66 (2017), 1026–1028.
26. Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B.G., Zhou, H.H., Tybjaerg-Hansen, A., et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46 (2014), 352–356.
27. Holmen, O.L., Zhang, H., Fan, Y., Hovelson, D.H., Schmidt, E.M., Zhou, W., et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 46 (2014), 345–351.
28. Dongiovanni, P., Petta, S., Maglio, C., Fracanzani, A.L., Pipitone, R., Mozzi, E., et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61 (2015), 506–514.
29. Liu, Y.L., Reeves, H.L., Burt, A.D., Tiniakos, D., McPherson, S., Leathart, J.B., et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun, 5, 2014, 4309.
30. Luukkonen, P.K., Zhou, Y., Nidhina Haridas, P.A., Dwivedi, O.P., Hyotylainen, T., Ali, A., et al. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. J Hepatol 67 (2017), 128–136.
31. Kim, D.S., Jackson, A.U., Li, Y.K., Stringham, H.M., Kuusisto, J., Kangas, A.J., et al. Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apolipoprotein B-100 particles in Finns. J Lipid Res 58 (2017), 1471–1481.
32. Mancina, R.M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of european descent. Gastroenterology 150 (2016), 1219–1230 e1216.
33. Luukkonen, P.K., Zhou, Y., Hyotylainen, T., Leivonen, M., Arola, J., Orho-Melander, M., et al. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol 65 (2016), 1263–1265.
34. Donati, B., Dongiovanni, P., Romeo, S., Meroni, M., McCain, M., Miele, L., et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci Rep, 7, 2017, 4492.
35. Speliotes, E.K., Yerges-Armstrong, L.M., Wu, J., Hernaez, R., Kim, L.J., Palmer, C.D., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet, 7, 2011, e1001324.
36. Santoro, N., Zhang, C.K., Zhao, H., Pakstis, A.J., Kim, G., Kursawe, R., et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 55 (2011), 781–789.
37. Petta, S., Miele, L., Bugianesi, E., Camma, C., Rosso, C., Boccia, S., et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic Fatty liver disease. PLoS One, 9, 2014, e87523.
38. Valenti, L., Alisi, A., Nobili, V., Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology 55 (2012), 661–663.
39. Beer, N.L., Tribble, N.D., Mcculloch, L.J., Roos, C., Johnson, P.R., Orho-melander, M., et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18 (2009), 4081–4088.
40. Dongiovanni, P., Rametta, R., Fracanzani, A.L., Benedan, L., Borroni, V., Maggioni, P., et al. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol, 10, 2010, 102.
41. Dongiovanni, P., Valenti, L., Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility?. PPAR Res, 2013, 2013, 452061.
42. Kumari, M., Schoiswohl, G., Chitraju, C., Paar, M., Cornaciu, I., Rangrez, A.Y., et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic Acid acyltransferase. Cell Metab 15 (2012), 691–702.
43. Valenti, L., Motta, B.M., Alisi, A., Sartorelli, R., Buonaiuto, G., Dongiovanni, P., et al. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 54 (2012), 588–593.
44. Caldwell, S.H., Swerdlow, R.H., Khan, E.M., Iezzoni, J.C., Hespenheide, E.E., Parks, J.K., et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 31 (1999), 430–434.
45. Berardi, M.J., Chou, J.J., Fatty acid flippase activity of UCP2 is essential for its proton transport in mitochondria. Cell Metab 20 (2014), 541–552.
46. Fares, R., Petta, S., Lombardi, R., Grimaudo, S., Dongiovanni, P., Pipitone, R., et al. The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. Liver Int 35 (2015), 1574–1580.
47. Sutton, A., Khoury, H., Prip-Buus, C., Cepanec, C., Pessayre, D., Degoul, F., The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13 (2003), 145–157.
48. Al-Serri, A., Anstee, Q.M., Valenti, L., Nobili, V., Leathart, J.B., Dongiovanni, P., et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 56 (2012), 448–454.
49. Namikawa, C., Shu-Ping, Z., Vyselaar, J.R., Nozaki, Y., Nemoto, Y., Ono, M., et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J Hepatol 40 (2004), 781–786.
50. Valenti, L., Fracanzani, A.L., Bugianesi, E., Dongiovanni, P., Galmozzi, E., Vanni, E., et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 138 (2010), 905–912.
51. Valenti, L., Canavesi, E., Galmozzi, E., Dongiovanni, P., Rametta, R., Maggioni, P., et al. Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 53 (2010), 927–933.
52. Valenti, L., Rametta, R., Dongiovanni, P., Motta, B.M., Canavesi, E., Pelusi, S., et al. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS One, 7, 2012, e48804.
53. Dongiovanni, P., Valenti, L., Rametta, R., Daly, A.K., Nobili, V., Mozzi, E., et al. Genetic variants regulating Insulin Receptor signaling are associated with the severity of liver damage in patients with nonalcoholic fatty liver disease. Gut 59 (2010), 267–273.
54. Anstee, Q.M., Darlay, R., Leathart, J.B., Clement, J., Clement, K., Aithal, G.P., et al. Genome-wide association analysis confirms importance of PNPLA3 and identifies novel variants associated with histologically progressive steatohepatitis in NAFLD. Hepatology 56 (2012), 265A–266A.
55. Kitamoto, A., Kitamoto, T., Nakamura, T., Ogawa, Y., Yoneda, M., Hyogo, H., et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J 61 (2014), 683–689.
56. Ishizuka, Y., Nakayama, K., Ogawa, A., Makishima, S., Boonvisut, S., Hirao, A., et al. TRIB1 downregulates hepatic lipogenesis and glycogenesis via multiple molecular interactions. J Mol Endocrinol 52 (2014), 145–158.
57. Makishima, S., Boonvisut, S., Ishizuka, Y., Watanabe, K., Nakayama, K., Iwamoto, S., Sin3A-associated protein, 18 kDa, a novel binding partner of TRIB1, regulates MTTP expression. J Lipid Res 56 (2015), 1145–1152.
58. Petta, S., Valenti, L., Svegliati-Baroni, G., Ruscica, M., Pipitone, R.M., Dongiovanni, P., et al. Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with Nonalcoholic fatty liver disease. J Clin Endocrinol Metab 102 (2017), 2660–2669.
59. Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49 (2009), 1877–1887.
60. Valenti, L., Fracanzani, A.L., Dongiovanni, P., Santorelli, G., Branchi, A., Taioli, E., et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122 (2002), 274–280.
61. Pastor, I.J., Laso, F.J., Romero, A., Gonzalez-Sarmiento, R., 238 G>A polymorphism of tumor necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. Alcohol Clin Exp Res 29 (2005), 1928–1931.
62. Gochee, P.A., Jonsson, J.R., Clouston, A.D., Pandeya, N., Purdie, D.M., Powell, E.E., Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol 18 (2003), 386–392.
63. Eslam, M., McLeod, D., Kelaeng, K.S., Mangia, A., Berg, T., Thabet, K., et al. IFN-lambda3, not IFN-lambda4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat Genet 49 (2017), 795–800.
64. Petta, S., Grimaudo, S., Camma, C., Cabibi, D., Marco, V.D., Licata, G., et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 56 (2012), 1356–1362.
65. Eslam, M., Hashem, A.M., Leung, R., Romero-Gomez, M., Berg, T., Dore, G.J., et al. Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun, 6, 2015, 6422.
66. Petta, S., Valenti, L., Tuttolomondo, A., Grimaudo, S., Dongiovanni, P., Pipitone, R.M., et al. IFNL4 rs368234815 δG>TT variant is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Hepatology, 2017, 10.1002/hep.29395.
67. Petta, S., Valenti, L., Marra, F., Grimaudo, S., Tripodo, C., Bugianesi, E., et al. MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. J Hepatol 64 (2016), 682–690.
68. Rueger, S., Bochud, P.Y., Dufour, J.F., Mullhaupt, B., Semela, D., Heim, M.H., et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut 64 (2015), 1605–1615.
69. Musso, G., Cassader, M., De Michieli, F., Paschetta, E., Pinach, S., Saba, F., et al. MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat. Hum Mol Genet 26 (2017), 1747–1758.
70. Calado, R.T., Regal, J.A., Kleiner, D.E., Schrump, D.S., Peterson, N.R., Pons, V., et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One, 4, 2009, e7926.
71. Hartmann, D., Srivastava, U., Thaler, M., Kleinhans, K.N., N'Kontchou, G., Scheffold, A., et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology 53 (2011), 1608–1617.
72. Aravinthan, A., Mells, G., Allison, M., Leathart, J., Kotronen, A., Yki-Jarvinen, H., et al. Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. Cell Cycle 13 (2014), 1489–1494.
73. Valenti, L., Dongiovanni, P., CDKN1A: a double-edged sword in fatty liver?. Cell Cycle 13 (2014), 1371–1372.
74. Miele, L., Beale, G., Patman, G., Nobili, V., Leathart, J., Grieco, A., et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 135 (2008), 282–291.
75. Bechmann, L.P., Gastaldelli, A., Vetter, D., Patman, G.L., Pascoe, L., Hannivoort, R.A., et al. Glucokinase links Kruppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology 55 (2012), 1083–1093.
76. Bruce, K.D., Cagampang, F.R., Argenton, M., Zhang, J., Ethirajan, P.L., Burdge, G.C., et al. Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. Hepatology 50 (2009), 1796–1808.
77. Breij, L.M., Kerkhof, G.F., Hokken-Koelega, A.C., Accelerated infant weight gain and risk for nonalcoholic fatty liver disease in early adulthood. J Clin Endocrinol Metab 99 (2014), 1189–1195.
78. Nobili, V., Marcellini, M., Marchesini, G., Vanni, E., Manco, M., Villani, A., et al. Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes Care 30 (2007), 2638–2640.
79. Suomela, E., Oikonen, M., Pitkänen, N., Ahola-Olli, A., Virtanen, J., Parkkola, R., et al. Childhood predictors of adult fatty liver. The cardiovascular risk in young finns study. J Hepatol 65 (2016), 784–790.
80. Valenti, L., Romeo, S., Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood. J Hepatol 65 (2016), 668–670.
81. Dudley, K.J., Sloboda, D.M., Connor, K.L., Beltrand, J., Vickers, M.H., Offspring of mothers fed a high fat diet display hepatic cell cycle inhibition and associated changes in gene expression and DNA methylation. PLoS One, 6, 2011, e21662.
82. Horvath, S., Erhart, W., Brosch, M., Ammerpohl, O., von Schonfels, W., Ahrens, M., et al. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci U S A 111 (2014), 15538–15543.
83. Pirola, C.J., Gianotti, T.F., Burgueno, A.L., Rey-Funes, M., Loidl, C.F., Mallardi, P., et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 62 (2013), 1356–1363.
84. Sookoian, S., Rosselli, M.S., Gemma, C., Burgueno, A.L., Fernandez Gianotti, T., Castano, G.O., et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology 52 (2010), 1992–2000.
85. Pogribny, I.P., Tryndyak, V.P., Bagnyukova, T.V., Melnyk, S., Montgomery, B., Ross, S.A., et al. Hepatic epigenetic phenotype predetermines individual susceptibility to hepatic steatosis in mice fed a lipogenic methyl-deficient diet. J Hepatol 51 (2009), 176–186.
86. Murphy, S.K., Yang, H., Moylan, C.A., Pang, H., Dellinger, A., Abdelmalek, M.F., et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology 145 (2013), 1076–1087.
87. Kitamoto, T., Kitamoto, A., Ogawa, Y., Honda, Y., Imajo, K., Saito, S., et al. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. J Hepatol 63 (2015), 494–502.
88. Ahrens, M., Ammerpohl, O., von Schonfels, W., Kolarova, J., Bens, S., Itzel, T., et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 18 (2013), 296–302.
89. Sookoian, S., Puri, P., Castano, G.O., Scian, R., Mirshahi, F., Sanyal, A.J., et al. Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency. Liver Int 37 (2017), 611–619.
90. Cohen, H.Y., Miller, C., Bitterman, K.J., Wall, N.R., Hekking, B., Kessler, B., et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305 (2004), 390–392.
91. Brooks, C.L., Gu, W., How does SIRT1 affect metabolism, senescence and cancer?. Nat Rev Cancer 9 (2009), 123–128.
92. Frescas, D., Valenti, L., Accili, D., Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 280 (2005), 20589–20595.
93. Mukhopadhyay, P., Horvath, B., Rajesh, M., Varga, Z.V., Gariani, K., Ryu, D., et al. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. J Hepatol 66 (2017), 589–600.
94. Huang, K., Du, M., Tan, X., Yang, L., Li, X., Jiang, Y., et al. PARP1-mediated PPARalpha poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease. J Hepatol 66 (2017), 962–977.
95. Gariani, K., Ryu, D., Menzies, K.J., Yi, H.S., Stein, S., Zhang, H., et al. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. J Hepatol 66 (2017), 132–141.
96. Cao, Y., Xue, Y., Xue, L., Jiang, X., Wang, X., Zhang, Z., et al. Hepatic menin recruits SIRT1 to control liver steatosis through histone deacetylation. J Hepatol 59 (2013), 1299–1306.
97. Zeybel, M., Hardy, T., Wong, Y.K., Mathers, J.C., Fox, C.R., Gackowska, A., et al. Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med 18 (2012), 1369–1377.
98. Zeybel, M., Hardy, T., Robinson, S.M., Fox, C., Anstee, Q.M., Ness, T., et al. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin Epigenetics, 7, 2015, 25.
99. Hardy, T., Zeybel, M., Day, C.P., Dipper, C., Masson, S., McPherson, S., et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut 66 (2017), 1321–1328.
100. Cheung, O., Puri, P., Eicken, C., Contos, M.J., Mirshahi, F., Maher, J.W., et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48 (2008), 1810–1820.
101. Gerhard, G.S., DiStefano, J.K., Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol 7 (2015), 226–234.
102. Zarrinpar, A., Gupta, S., Maurya, M.R., Subramaniam, S., Loomba, R., Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut 65 (2016), 1546–1554.
103. Hsu, S.H., Wang, B., Kota, J., Yu, J., Costinean, S., Kutay, H., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122 (2012), 2871–2883.
104. Csak, T., Bala, S., Lippai, D., Satishchandran, A., Catalano, D., Kodys, K., et al. MicroRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int 35 (2015), 532–541.
105. Pirola, C.J., Fernandez Gianotti, T., Castano, G.O., Mallardi, P., San Martino, J., Ledesma, Mora Gonzalez Lopez, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64 (2015), 800–812.
106. Calo, N., Ramadori, P., Sobolewski, C., Romero, Y., Maeder, C., Fournier, M., et al. Stress-activated miR-21/miR-21∗ in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. Gut 65 (2016), 1871–1881.
107. Wu, H., Ng, R., Chen, X., Steer, C.J., Song, G., MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut 65 (2016), 1850–1860.
108. Xu, Y., Zalzala, M., Xu, J., Li, Y., Yin, L., Zhang, Y., A metabolic stress-inducible miR-34a-HNF4alpha pathway regulates lipid and lipoprotein metabolism. Nat Commun, 6, 2015, 7466.
109. Povero, D., Eguchi, A., Li, H., Johnson, C.D., Papouchado, B.G., Wree, A., et al. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One, 9, 2014, e113651.
110. Tan, Y., Ge, G., Pan, T., Wen, D., Gan, J., A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One, 9, 2014, e105192.
111. Global Lipids Genetics, C., Willer, C.J., Schmidt, E.M., Sengupta, S., Peloso, G.M., Gustafsson, S., et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 45 (2013), 1274–1283.
112. Romeo, S., Sentinelli, F., Dash, S., Yeo, G.S., Savage, D.B., Leonetti, F., et al. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond) 34 (2010), 190–194.
113. Stender, S., Kozlitina, J., Nordestgaard, B.G., Tybjaerg-Hansen, A., Hobbs, H.H., Cohen, J.C., Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 49 (2017), 842–847.
114. Davis, J.N., Le, K.A., Walker, R.W., Vikman, S., Spruijt-Metz, D., Weigensberg, M.J., et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 92 (2011), 1522–1527.
115. Nobili, V., Liccardo, D., Bedogni, G., Salvatori, G., Gnani, D., Bersani, I., et al. Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. Genes Nutr, 9, 2014, 392.
116. Buch, S., Stickel, F., Trepo, E., Way, M., Herrmann, A., Nischalke, H.D., et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 47 (2015), 1443–1448.
117. Valenti, L., Fracanzani, A.L., Fargion, S., The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?. Semin Immunopathol 31 (2009), 359–369.
118. Sookoian, S., Pirola, C.J., Meta-analysis of the influence of TM6SF2 E167K variant on Plasma Concentration of Aminotransferases across different Populations and Diverse Liver Phenotypes. Sci Rep, 6, 2016, 27718.
119. Milano, M., Aghemo, A., Mancina, R.M., Fischer, J., Dongiovanni, P., De Nicola, S., et al. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology 62 (2015), 111–117.
120. Thabet, K., Asimakopoulos, A., Shojaei, M., Romero-Gomez, M., Mangia, A., Irving, W.L., et al. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nat Commun, 7, 2016, 12757.
121. Thabet, K., Chan, H.L., Petta, S., Mangia, A., Berg, T., Boonstra, A., et al. The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Hepatology 65 (2017), 1840–1850.
122. Eslam, M., Mangia, A., Berg, T., Chan, H.L., Irving, W.L., Dore, G.J., et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology 64 (2016), 34–46.
123. Kraft, P., Wacholder, S., Cornelis, M.C., Hu, F.B., Hayes, R.B., Thomas, G., et al. OPINION Beyond odds - ratios communicating disease risk based on genetic profiles. Nat Rev Genet 10 (2009), 264–269.
124. Trepo, E., Romeo, S., Zucman-Rossi, J., Nahon, P., PNPLA3 gene in liver diseases. J Hepatol 65 (2016), 399–412.
125. Jakobsdottir, J., Gorin, M.B., Conley, Y.P., Ferrell, R.E., Weeks, D.E., Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet, 5, 2009, e1000337.
126. Petta, S., Grimaudo, S., Camma, C., Cabibi, D., Di Marco, V., Licata, G., et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol 56 (2012), 1356–1362.
127. Eslam, M., Hashem, A.M., Romero-Gomez, M., Berg, T., Dore, G.J., Mangia, A., et al. FibroGENE: A gene-based model for staging liver fibrosis. J Hepatol 64 (2016), 390–398.
128. Qian, D.C., Han, Y.H., Byun, J.Y., Shin, H.R., Hung, R.J., McLaughlin, J.R., et al. A novel pathway-based approach improves lung cancer risk prediction using germline genetic variations. Cancer Epidem Biomar 25 (2016), 1208–1215.
129. Shen, J., Wong, G.L., Chan, H.L., Chan, R.S., Chan, H.Y., Chu, W.C., et al. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 30 (2015), 139–146.
130. Sevastianova, K., Kotronen, A., Gastaldelli, A., Perttila, J., Hakkarainen, A., Lundbom, J., et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 94 (2011), 104–111.
131. Marzuillo, P., Grandone, A., Perrone, L., del Giudice, E.M., Weight loss allows the dissection of the interaction between abdominal fat and PNPLA3 (adiponutrin) in the liver damage of obese children. J Hepatol 59 (2013), 1143–1144.
132. Teslovich, T.M., Musunuru, K., Smith, A.V., Edmondson, A.C., Stylianou, I.M., Koseki, M., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466 (2010), 707–713.
133. Di Filippo, M., Moulin, P., Roy, P., Samson-Bouma, M.E., Collardeau-Frachon, S., Chebel-Dumont, S., et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. J Hepatol 61 (2014), 891–902.
134. Dongiovanni, P., Valenti, L., Genetics of nonalcoholic fatty liver disease. Metab Clin Exp 65 (2016), 1026–1037.
135. Becker, P.P., Rau, M., Schmitt, J., Malsch, C., Hammer, C., Bantel, H., et al. Performance of serum microRNAs -122, -192 and -21 as biomarkers in patients with non-alcoholic steatohepatitis. PLoS One, 10, 2015, e0142661.
136. Liu, X.L., Pan, Q., Zhang, R.N., Shen, F., Yan, S.Y., Sun, C., et al. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol 22 (2016), 9844–9852.
137. Leti, F., Malenica, I., Doshi, M., Courtright, A., Van Keuren-Jensen, K., Legendre, C., et al. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl Res 166 (2015), 304–314.